Christopher Rivera
Direktor/Vorstandsmitglied bei HAPBEE TECHNOLOGIES, INC.
Vermögen: - $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Charles McNerney | M | 68 |
EMulate Therapeutics, Inc.
 EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 8 Jahre |
| George A Gates | M | - |
Otonexus Medical Technologies, Inc.
 Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | 13 Jahre |
| Karl A. Mulligan | M | - |
CV6 Therapeutics (NI) Ltd.
 CV6 Therapeutics (NI) Ltd. Pharmaceuticals: MajorHealth Technology CV6 Therapeutics (NI) Ltd. develops and manufactures pharmaceutical drugs. The company is based in Belfast, UK. The British company was founded in 2013 by Robert D. Ladner, Karl A. Mulligan. Robert D. Ladner has been the CEO since 2013. | - |
| Robert D. Ladner | M | - |
CV6 Therapeutics (NI) Ltd.
CV6 Therapeutics (NI) Ltd. Pharmaceuticals: MajorHealth Technology CV6 Therapeutics (NI) Ltd. develops and manufactures pharmaceutical drugs. The company is based in Belfast, UK. The British company was founded in 2013 by Robert D. Ladner, Karl A. Mulligan. Robert D. Ladner has been the CEO since 2013. | - |
| Steven Pope | M | 71 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 14 Jahre |
| Yona Shtern | M | - | 3 Jahre | |
| Caitlin Cameron | F | - |
Otonexus Medical Technologies, Inc.
Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | 12 Jahre |
| Mark A. Moehring | M | - |
Otonexus Medical Technologies, Inc.
Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | - |
| Richard Henriques | M | 68 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 9 Jahre |
| Donna Morgan Murray | M | 67 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 7 Jahre |
| Kyle J. Kingma | M | 40 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 14 Jahre |
| Kenny Adessky | M | - | - | |
| John Kingma | M | 65 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 22 Jahre |
| Bennett M. Butters | M | 75 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 22 Jahre |
| Mark Timm | M | - | 4 Jahre | |
| Andrew W. Daniels | M | 67 |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 7 Jahre |
| Richard Alexander Milliken | M | 73 |
CV6 Therapeutics (NI) Ltd.
CV6 Therapeutics (NI) Ltd. Pharmaceuticals: MajorHealth Technology CV6 Therapeutics (NI) Ltd. develops and manufactures pharmaceutical drugs. The company is based in Belfast, UK. The British company was founded in 2013 by Robert D. Ladner, Karl A. Mulligan. Robert D. Ladner has been the CEO since 2013. | - |
| Michael Matysik | M | 64 | 4 Jahre | |
| Robert Dzisiak | M | 61 | 5 Jahre | |
| David Matteson | M | - |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 12 Jahre |
| James J. Poliero | M | - |
CV6 Therapeutics (NI) Ltd.
CV6 Therapeutics (NI) Ltd. Pharmaceuticals: MajorHealth Technology CV6 Therapeutics (NI) Ltd. develops and manufactures pharmaceutical drugs. The company is based in Belfast, UK. The British company was founded in 2013 by Robert D. Ladner, Karl A. Mulligan. Robert D. Ladner has been the CEO since 2013. | - |
| Robert D. Comfort | M | - |
CV6 Therapeutics (NI) Ltd.
CV6 Therapeutics (NI) Ltd. Pharmaceuticals: MajorHealth Technology CV6 Therapeutics (NI) Ltd. develops and manufactures pharmaceutical drugs. The company is based in Belfast, UK. The British company was founded in 2013 by Robert D. Ladner, Karl A. Mulligan. Robert D. Ladner has been the CEO since 2013. | - |
| Mitch Kujavsky | M | - | 2 Jahre | |
| Xavier A. Figueroa | M | - |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 8 Jahre |
| Brain Mogen | M | - | - | |
| Iggy Rodriguez | M | - | 3 Jahre | |
| Jordan Neville | M | - | 3 Jahre | |
| Charlie Corredor | M | - |
Otonexus Medical Technologies, Inc.
Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | 7 Jahre |
| Éric Brassard | M | - | 3 Jahre | |
| Marion Foote | F | 78 |
Otonexus Medical Technologies, Inc.
Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | - |
| Harris Brody | M | - |
Otonexus Medical Technologies, Inc.
Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | - |
| Rhonda F. Rhyne | F | 63 |
Otonexus Medical Technologies, Inc.
Otonexus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Otonexus Medical Technologies, Inc. is a holding company engages in health care industry. The firm designs, develops, and commercializes an ultrasound medical device that diagnoses middle ear infections in children and adults. The company was founded by Gerge A. Gates and Mark A. Moehring and is headquartered in Seattle, WA. | 12 Jahre |
| Jon Sheeri | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Scott Donnell | M | 37 | - | |
| Jeffrey Farrow | M | 62 | - | |
| Ashley C. Gould | F | 49 | - | |
| Donald Santel | M | 62 | 8 Jahre | |
| Lota Zoth | F | 64 | 7 Jahre | |
| Daniel Welch | M | 66 | 3 Jahre | |
| Christine Nash | F | 51 | - | |
| Sylvia R. Wheeler | F | 63 | 1 Jahre | |
| Klara Dickinson-Eason | F | 57 | 7 Jahre | |
| Bo Jesper Hansen | M | 66 | 4 Jahre | |
| George T. Jue | M | 71 | - | |
| James Healy | M | 58 | 9 Jahre | |
| David Gryska | M | 68 | 4 Jahre | |
| Thomas Wiggans | M | 72 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 Jahre |
| Dion F. Coakley | M | - | - | |
| Brent Dobsch | M | - | - | |
| Bijan Salehizadeh | M | - | 9 Jahre | |
| Mark E. Spring | M | - | - | |
| Lesley Calhoun | F | 58 | 2 Jahre | |
| Yannick Desjardins | M | - | 2 Jahre | |
| Wayne T. Hockmeyer | M | 79 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | - |
| Bruce F. Scharschmidt | M | 78 | - | |
| Herrick Lau | M | 58 | - | |
| Natalie Holles | F | 51 | 2 Jahre | |
| James A. Kaser | M | - | - | |
| Jake Nunn | M | 53 | 6 Jahre | |
| Timothy Patrick Lynch | M | 54 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 3 Jahre |
| H. Perez | M | 74 | - | |
| Gaurav Aggarwal | M | 51 | 4 Jahre | |
| Ajay Bansal | M | 62 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 2 Jahre |
| Theodore Schroeder | M | 69 | 1 Jahre | |
| Thomas H. Silberg | M | 76 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 Jahre |
| Michael Astrue | M | 67 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 Jahre |
| William Ringo | M | 78 | - | |
| Eric Peterson | M | - |
EMulate Therapeutics, Inc.
EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 48 | 70,59% |
| Kanada | 17 | 25,00% |
| Vereinigtes Königreich | 5 | 7,35% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Christopher Rivera
- Persönliches Netzwerk
